Атеротромбоз (May 2018)

EVALUATING THE USE OF PITAVASTATIN IN TYPE 2 DIABETES MELLITUS AND HIGH CARDIOVASCULAR RISK: CLINICAL CASE

  • M. N. Mamedov,
  • М. A. Kolchina

DOI
https://doi.org/10.21518/2307-1109-2018-1-132-139
Journal volume & issue
Vol. 0, no. 1
pp. 132 – 139

Abstract

Read online

The review article presents data on the management of lipid storage disease in patients with diabetes mellitus (DM). A clinical case of a patient with diabetes and high cardiovascular risk caused by severe hyperlipidemia among other things is provided for illustrative purposes. The article reviews the results of clinical studies of the efficacy and safety of Pitavastatin in patients with cardiometabolic disorders. The dynamics of the lipid spectrum and glycaemia indicators against the background of course therapy with Pitavastatin at a daily dose of 4 mg in combination with the diet therapy is monitored in patients with diabetes.

Keywords